ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Palliative and Supportive Care

ASCO 2016 Genitourinary Cancers Symposium

Cancer Network presents exclusive coverage from the American Society of Clinical Oncology (ASCO) 2016 Genitourinary Cancers Symposium, held January 7–9 in San Francisco. We’ll bring you reports as we cover the latest research, trials, scientific advances, and controversies that are changing the way genitourinary cancers are managed and treated.

Palliative and Supportive Care

The FDA has approved the first single-dose intravenous NK1 receptor antagonist, fosaprepitant dimeglumine (Emend), for the treatment of nausea and vomiting that can accompany the use of moderately and highly emetogenic chemotherapy.

In this interview we discuss the use of video to facilitate shared decision-making in the palliative care setting and improve patient understanding regarding goals of care.

A drug commonly given to cancer patients to relieve opioid-induced constipation is capable of slowing tumor growth and may play a role in developing new drug therapies.

Palliative care should be provided with cancer care early in the course of illness for all patients with advanced disease, according to a new guidance statement from ASCO and the American Academy of Hospice and Palliative Medicine.

A novel program combining radiation oncology with palliative care in patients with painful bone metastases increased the use of proven treatments while maintaining pain management, decreased palliative radiation use, and decreased hospital length of stay.

Almost 40% of patients undergoing palliative radiotherapy to treat symptomatic bone metastases experienced pain flare, according to an observational study.

According to a recent study, treatments aimed at preventing skeletal-related events in patients with advanced cancer and bone metastases could reduce pain and the need for opioids.

Pages

Subscribe to Palliative and Supportive Care on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.